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The genomic landscape of children with acute myeloid leukemia (AML) who do not carry any cytogenetic abnormality
(CN-AML) is particularly heterogeneous and challenging, being characterized by different clinical outcomes. To provide
new genetic insights into this AML subset, we analyzed through RNA-seq 13 pediatric CN-AML cases, corroborating our
findings in an independent cohort of 168 AML patients enrolled in the AIEOP AML 2002/01 study. We identified a
chimeric transcript involving NUP98 and PHF23, resulting from a cryptic t(11;17)(p15;p13) translocation, demonstrating,
for the first time, that NUP98-PHF23 is a novel recurrent (2.6 %) abnormality in pediatric CN-AML.
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Childhood acute myeloid leukemia (AML) is a heteroge-
neous disease with current survival rates of approximately
60–70 %. Cytogenetics, recurrent molecular abnormalities,
and early response to treatment are the main factors influ-
encing outcome [1]. However, around 20 % of pediatric
AML do not carry any known cytogenetic abnormality
(cytogenetically normal-AML or CN-AML). In order to
shed light on this subgroup we performed whole-
transcriptome sequencing (WTS) in 13 pediatric CN-
AML cases, corroborating relevant findings in an inde-
pendent cohort of 168 cases.
Sequencing was performed on a HiScanSQ sequencer
(Illumina), and bioinformatic analysis was performed as
previously described [2]. In 2 (CN-AML_54, CN-AML_66)
out of 13 cases analyzed, we identified a chimeric tran-
script involving nucleoporin 98 kDa (NUP98) and PHD
finger protein 23 (PHF23) genes, resulting from a cryptic
translocation t(11;17)(p15;p13) (Fig. 1a and Table 1). In
both cases, we identified an in-frame fusion between
NUP98 exon 13 and PHF23 exon 4 (Fig. 1b). To date, the* Correspondence: riccardo.masetti@gmail.com
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only once in an adult AML patient [3], but never in a
pediatric AML cohort. Different from what was previously
reported by Reader and colleagues [3], in this study the re-
current breakpoint in PHF23 was always identified at the
beginning of exon 4 and not within it (Fig. 1a and b).
To assess the incidence of NUP98-PHF23 fusion in
pediatric CN-AML, we examined through RT-PCR ana-
lysis and Sanger sequencing a validation cohort of 168
AML children enrolled in the AIEOP AML 2002/01
study [4]; one-hundred thirty-nine patients (76 males
and 63 females, median age at diagnosis 7.7 years, range
17 days to 17.9 years) were negative for known recurrent
genetic abnormalities involving MLL, CBFB, and FLT3,
while the remaining 29 patients (15 males and 14 fe-
males, median age at diagnosis 11.8 years, range 3 to
17.4 years) harbored internal tandem duplication of
FLT3 (FLT3-ITD), this latter abnormality being chosen
because we previously reported a strong association be-
tween NUP98-NSD1 rearrangement and FLT3-ITD [5].
With the exception of FAB M3 (acute promyelocytic
leukemia), all the FAB types were represented in the val-
idation cohort. RNA was extracted from fresh bone mar-
row at diagnosis, and multiplex RT-PCR was used.
Sequencing by Sanger method was applied to all casesicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Identification of NUP98-PHF23 in pediatric CN-AML. a Schematic representation of NUP98-PHF23 fusion identified by RNA-seq in pediatric
CN-AML. Fusion occurs between exon 13 of NUP98 and exon 4 of PHF23. b Electropherogram from Sanger sequencing of the region surrounding
the breakpoint confirmed the in-frame fusion. A black arrow indicates the fusion breakpoint, predicted sequence of the fusion protein is shown.
c FISH analysis was performed on metaphases and interphase cells using three BlueFISH probes (BlueGnome Ltd., Cambridge), according to the
manufacturer’s instructions. BAC clones RP11-120E20 and RP11-348A20 (red) were used to probe the NUP98 gene on chromosome 11, while the
BAC clone RP11-542C16 (green) was used to target the PHF23 gene on chromosome 17. Normal metaphases (upper left) and interphase nuclei
(upper right) showed two red signals representing normal copies of NUP98 and two green signals representing normal copies of PHF23. Abnormal
metaphases (lower left) and interphase cells (lower right) containing the NUP98-PHF23 fusion gene showed one red (NUP98), one green (PHF23)
and one yellow fusion signal, which represents the juxtaposition of the translocated portions of the two genes
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2 out of 139 CN-AML cases were found to harbor
NUP98-PHF23 (Table 1). NUP98-PHF23 was not found
in any patient harboring FLT3-ITD. Fluorescence in-situ
hybridization confirmed the cryptic chromosomal trans-
location t(7;11)(p15;p13) leading to the fusion between
NUP98 and PHF23 in all cases (Fig. 1c).
So far, many NUP98-rearrangements have been found
to be associated with both de novo and therapy-related
AML but also with T-cell acute lymphoblastic leukemia
with over 28 different partner genes [6]. Recently, theTable 1 Clinical features of pediatric CN-AML patients harboring the




CN-AML_54a 2.9 M 187 M1 90 N
CN-AML_66a 9.0 M 1.2 M0 70 N
CN-AML_3 9.7 M 6.9 M4 40 N
CN-AML_4 7.0 M 1.8 M5A 54 N
AUTO autologous, CR complete remission, HSCT hematopoietic stem cell transplanta
apatients identified by RNA-seq
bdead patientfusion NUP98-JARID1A has been described to be a recur-
rent event in pediatric acute megakaryoblastic leukemia
(11 %), with a distinct HOX gene-expression pattern [7].
Conversely, chromosomal rearrangements and/or muta-
tions of PHF23 have never been previously described in
children with AML. Located on the reverse strand of
17p13.1, PHF23 encodes for a protein containing a plant
homeodomain (PHD) finger [8] involved in chromatin
remodeling [3]. Expression of NUP98-PHF23 has been
demonstrated to impair the differentiation of myeloid pro-
genitor cells and promote leukemia development in vitroNUP98-PHF23 fusion gene
tramedullary
volvement











o Yes (AUTO) Yes Yes (BM) 5 30b
o Yes (MUD) Yes – 65 66
o Yes (MUD) Yes – 40 41
o Yes (AUTO) Yes – 103 104
tion, MUD matched unrelated donor, BM bone marrow, WBC white blood cells
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sitive to disulfiram, an FDA-approved drug, demonstrating
the feasibility of targeting this oncoprotein [9].
In summary, we identified, for the first time in child-
hood AML, a NUP98-PHF23 fusion, demonstrating that
this genomic aberrancy is not exceptional (tentative fre-
quency of 2.6 %) in pediatric CN-AML. These findings en-
force the role of epigenetic regulators in pediatric AML
and suggest novel therapeutic targets for this disease.
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